PHGE BiomX Inc.

NEUTRAL Impact: 2/10 8-K
Horizon weeks Filed May 28, 2026 Processed 12d 15h ago SEC 0001213900-26-061772
8-K context-dependent: Items 5.02
Latest settled — T+5d
PHGE ▼ -44.36% at T+5d
NEUTRAL call ✗ call lost -44.36% · α vs SPY -44.31% · entry $1.56 → $0.8680
Next anchor: T+20d in 16d
Currently $0.6815 · -56.31% from $1.56 entry
Entry anchored
May 28, 07:45 AM ET
via Databento tick
T+1d
-19.23%
call -19.23% · α -19.47%
$1.26
settled 12d ago
T+5d
-44.36%
call -44.36% · α -44.31%
$0.8680
settled 6d ago
T+20d
call — · α —
in 16d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

BiomX Inc. appointed Roy Rousso as Chief Business Officer (and, per the consulting agreement, COO/CBO) effective July 1, 2026, via a consulting agreement with $11,900/month base compensation at a 70% engagement level, plus eligibility for an annual performance bonus of up to $71,400 and a 200,000-share equity grant vesting over three years. This is a routine officer appointment with no material financial data or strategic changes disclosed, and no departures were announced.

Actionable Insight

Routine officer appointment with no stock-moving implications. Monitor for potential transition to full-time employment or changes in engagement level, but no immediate trading catalyst.

Key Facts

  • Appointed Roy Rousso as Chief Business Officer effective July 1, 2026
  • Consulting agreement: $11,900/month base fee (70% of full-time $17,000/month)
  • Annual performance bonus up to 50% of base fee (up to $71,400 per annum at 70% engagement)
  • Equity grant of 200,000 shares of common stock, vesting in 3 equal annual installments
  • 12-month post-termination non-compete and non-solicitation covenants
  • Part-time independent contractor arrangement; parties intend to transition to full-time salaried employment as business develops

Financial Impact

Annual cash compensation of approximately $142,800 in base fee plus up to $71,400 bonus potential at current engagement level; 200,000 share equity award with three-year vesting

operating expenses (SG&A)

Risk Factors

  • Part-time engagement may limit bandwidth relative to a full-time COO/CBO
  • Equity grant adds modest shareholder dilution (~200K shares vs $16M market cap)

Market Snapshot

Exchange
NYSE
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
75% bullish (8 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-061772
Document: ea0292479-8k_biomx.htm0001213900-26-061772
Document: 0001213900-26-061772-index-headers.html0001213900-26-061772
Document: 0001213900-26-061772-index.html0001213900-26-061772
Document: 0001213900-26-061772.txt0001213900-26-061772
7 reports for PHGE
Performance horizon
0% Hit rate 0 of 4 directional calls best @ T+1▼ −9.00%Apr 10, 2026
Filters
Rows
Reports for PHGE — sortable, filterable
Type Now
May 28, 2026
12d ago
8-K
NEUTRAL ★ 2/10
$1.56 $0.8680▼ −44.36%▼ −44.31%$0.6815 (−56.31%)
Apr 30, 2026
5w ago
10-K/A
NEUTRAL ★ 3/10
$0.7900 $0.6270▼ −20.63%▼ −22.98%$0.6815 (−13.73%)
Apr 16, 2026
7w ago
8-K
NEUTRAL ★ 5/10
$1.84 $1.11▼ −39.67%▼ −40.23%$0.6815 (−62.96%)
Apr 13, 2026
8w ago
8-K
BULLISH ★ 7/10
$2.63 $1.46▼ −44.49%▼ −47.78%$0.6815 (−74.09%)
Apr 13, 2026
8w ago
Press Release
BULLISH ★ 7/10
$2.63 $1.46▼ −44.49%▼ −47.78%$0.6815 (−74.09%)
Apr 10, 2026
8w ago
8-K
BULLISH ★ 7/10
$2.89 $1.84▼ −36.33%▼ −40.84%$0.6815 (−76.42%)
Apr 10, 2026
8w ago
Press Release
BULLISH ★ 7/10
$2.89 $1.84▼ −36.33%▼ −40.84%$0.6815 (−76.42%)
Showing 7 of 7

US Market Status

Market Closed — Opens Thu (10h 10m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access